This course provides a practical overview of the molecular signaling pathways that drive both solid tumors and hematologic malignancies, and how these pathways are translated into therapeutic targets for cancer treatment. Participants will explore the biological mechanisms underlying oncogenesis, the identification and validation of drug targets, and the principles of developing targeted therapies and precision medicine approaches.
What You Will Learn
-
The fundamentals of oncogenic signaling and cancer biology.
-
Key signaling pathways involved in cancer initiation, progression, and resistance.
-
Differences and similarities between solid tumors and hematologic malignancies.
-
Strategies for identifying and validating therapeutic targets.
-
The drug discovery and development process, from preclinical research to clinical trials.
-
Mechanisms of action of targeted therapies, immunotherapies, and combination treatments.
-
Biomarker development and patient stratification in precision oncology.
-
Challenges and emerging trends in cancer drug development.
What You Will Gain
By the end of this course, participants will be able to:
-
Understand the molecular basis of cancer and its therapeutic implications.
-
Evaluate potential drug targets based on signaling pathway biology.
-
Interpret preclinical and clinical data relevant to oncology drug development.
-
Apply translational research principles to therapeutic development programs.
-
Recognize opportunities and challenges in developing novel cancer therapies.
-
Strengthen their knowledge of precision medicine and modern oncology treatment strategies.
Who Should Attend
This course is ideal for researchers, clinicians, pharmaceutical and biotechnology professionals, graduate students, and anyone interested in oncology, translational medicine, or cancer therapeutic development.
Learning Outcomes
Upon successful completion, participants will have a practical understanding of how discoveries in cancer signaling pathways are translated into innovative therapies that improve patient outcomes and advance precision oncology.
